false
--12-31
0001321834
0001321834
2024-07-22
2024-07-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 22, 2024
TNF
Pharmaceuticals, Inc.
(Exact
name of Registrant as specified in its charter)
| Delaware |
|
001-36268 |
|
22-2983783 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File No.) |
|
(IRS Employer
Identification No.) |
| 855 N. Wolfe Street,
Suite 623 |
|
|
| Baltimore, MD |
|
21205 |
| (Address of principal executive
offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (856) 848-8698
MyMD
Pharmaceuticals, Inc.
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
Registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common stock, par value
$0.001 per share |
|
TNFA |
|
The Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On
July 22, 2024, TNF Pharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Certificate
of Incorporation (the “Certificate of Amendment”) to change the name of the Company from “MyMD Pharmaceuticals, Inc.”
to “TNF Pharmaceuticals, Inc.”, effective as of July 22, 2024 (the “Name Change”). In addition, effective before
the open of market trading on July 24, 2024, the Company’s common stock ceased trading under the ticker symbol “MYMD”
and began trading on the Nasdaq Stock Market under the ticker symbol “TNFA” (“Symbol Change”).
The
Name Change does not affect the rights of the Company’s security holders. There will be no change to the Company’s CUSIP
in connection with the Name Change.
Pursuant
to Section 242 of the Delaware General Corporation Law, stockholder approval was not required to complete the Name Change or to approve
or effect the Certificate of Amendment. The information set forth herein is qualified in its entirety by reference to the complete text
of the Certificate of Amendment, a copy of which is filed with this report as Exhibit 3.1 and is incorporated by reference herein.
Item
7.01. Regulation FD Disclosure.
On
July 22, 2024, the Company issued a press release announcing the Name Change. A copy of the press release is furnished hereto as Exhibit
99.1 and incorporated by reference herein.
On
July 24, 2024, the Company issued a press release announcing the Symbol Change. A copy of the press release is furnished hereto as Exhibit
99.2 and incorporated by reference herein.
In
accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including
Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly
set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K
is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is
material or that the dissemination of such information is required by Regulation FD.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
TNF PHARMACEUTICALS, INC. |
| |
|
|
| Date: July 26, 2024 |
By: |
/s/
Joshua Silverman |
| |
Name: |
Joshua Silverman |
| |
Title: |
Director |
Exhibit
3.1
Certificate
of Amendment
of
Certificate of Incorporation
of
MYMD PHARMACEUTICALS, INC.
MyMD
Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware
(the “Corporation”) hereby certifies:
| 1. | The
original Certificate of Incorporation of the Corporation was filed with the Secretary of
State of Delaware on October 19, 2023 (the “Certificate of Incorporation”). |
| | | |
| 2. | The
Certificate of Incorporation was corrected by the Certificate of Correction thereto, filed
with the Secretary of State of Delaware on March 25, 2024. |
| | | |
| 3. | Resolutions
were duly adopted by the Board of Directors of the Corporation setting forth this proposed
amendment to the Certificate of Incorporation. |
| | | |
| 4. | Article
I of the Certificate of Incorporation is hereby amended and restated in its entirety to read
as follows: |
“The
name of the corporation is TNF Pharmaceuticals, Inc. (hereinafter referred to as the “Corporation”).
| 5. | The
foregoing amendment was duly adopted in accordance with the provisions of Section 242 of
the General Corporation Law of the State of Delaware. |
| | | |
| 6. | The
effective date of this Certificate of Amendment to the Certificate of Incorporation shall
be July 22, 2024. |
[Signature
page follows.]
IN
WITNESS WHEREOF, said corporation has caused this Certificate of Amendment to be executed this 22nd day of July, 2024.
| |
MyMD Pharmaceuticals,
Inc. |
| |
|
|
| |
By: |
/s/ Mitchell
Glass |
| |
Name: |
Mitchell Glass, M.D. |
| |
Title: |
President and Chief Medical Officer |
Exhibit
99.1
MyMD
Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.
New
name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system
Company
plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following statistically significant Phase 2 studies
TNF
Pharmaceuticals will begin trading on Nasdaq under the new trading symbol “TNFA” effective July 24, 2024
BALTIMORE
— July 22, 2024 — TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (the “Company”),
a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory
conditions, today announced a rebranding to the new name “TNF Pharmaceuticals, Inc.,” effective today. The Company’s
common stock, listed on the Nasdaq Capital Market, will begin trading under the new stock symbol “TNFA,” effective before
the market open on Wednesday, July 24, 2024.
“Our
new name, TNF Pharmaceuticals, is more closely aligned with our scientific focus on TNF-alpha, a protein in the body that plays a key
role in inflammation and autoimmunity,” said the Company’s President and Chief Medical Officer Mitchell Glass, M.D. “Excess
TNF-α in the blood or tissue can lead to diseases and disorders marked by acute or chronic inflammation, including age-related
disorders. Our lead clinical candidate, MYMD-1®, blocks the activity of excess TNF-alpha which supports restoration of control and
regulation of the immune system.”
MYMD-1
is a novel, orally dosed TNF-alpha (TNF-α) inhibitor drug for treating multiple conditions related to immune-metabolic dysregulation.
A successful and statistically significant small Phase 2 study was completed in 2023, evaluating the safety and efficacy of MYMD-1 as
a treatment for sarcopenia, the progressive loss of muscle mass and strength associated with aging.
“We
are moving forward with mid-stage clinical trials of MYMD-1 in sarcopenia based on positive clinical data from our Phase 2 trial and
previous research findings,” Dr. Glass continued. “We believe MYMD-1 could become a transformative treatment for TNF-alpha-based
autoimmune and inflammatory diseases including age-related conditions.”
MYMD-1
is distinguished from currently marketed TNF-α blockers in multiple ways. It is a first-in-class oral treatment shown to reduce
TNF-α and inflammation without infusion or injection. The drug’s ease of oral dosing is a strong advantage over currently
available TNF-α blockers, none of which are dosed orally. Unlike systemic therapies, our oral TNF alpha inhibitor can be dose adjusted
acutely and chronically for maximal safety and efficacy depending on the patient’s need.
TNF
Pharmaceuticals retains the registered trademark MYMD-1® for its lead drug program. The Company’s new Investors website address
is ir.tnfpharma.com.
About
TNF Pharmaceuticals, Inc.
TNF
Pharmaceuticals, Inc., formerly known as MyMD Pharmaceuticals, Inc., a clinical stage pharmaceutical company committed to extending healthy
lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms.
MYMD-1® is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which
drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders
marked by acute or chronic inflammation. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain,
addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve
upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs.
Cautionary
Statement Regarding Forward-Looking Statements
This
press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties
and other factors which may cause actual results, performance or achievements to be materially different from any expected future results,
performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates
assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,”
“estimate,” “expect,” “may,” “plan,” “will,” “would’’ and
other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results
to differ materially from those indicated by such forward-looking statements include, without limitation: the Company’s ability
to maintain compliance with the Nasdaq Stock Market’s listing standards; the timing of, and the Company’s ability to, obtain
and maintain regulatory approvals for clinical trials of the Company’s pharmaceutical candidates; the timing and results of the
Company’s planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical
candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in
which the Company operates; the Company’s ability to retain and attract senior management and other key employees; the Company’s
ability to quickly and effectively respond to new technological developments; and the Company’s ability to protect its trade secrets
or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the
Company’s proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2023, filed by the Company on April 1, 2024, and subsequent reports that the
Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the
Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future
events or otherwise.
Investor
Contact:
Robert
Schatz
(646) 421-9523
rschatz@tnfpharma.com
Exhibit
99.2
TNF
Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market
Open Today
New
name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system
BALTIMORE
— July 24, 2024 — TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (formerly MyMD Pharmaceuticals, Inc.) (the “Company”),
a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory
conditions, today announced that its common stock, listed on the Nasdaq Capital Market, begins trading under the new ticker symbol, “TNFA,”
effective before the market open today, July 24, 2024.
The
new trading symbol “TNFA” replaces the Company’s previous trading symbol “MYMD” and coincides with the
Company’s previously announced corporate name change to TNF Pharmaceuticals, Inc. The new corporate identity more accurately aligns
with the Company’s scientific focus on TNF-alpha (TNF-alpha tumor necrosis factor-alpha, or TNF-α), a protein in the body
that plays a key role in inflammation and autoimmunity. The Company’s lead clinical candidate, MYMD-1®, blocks the activity
of excess TNF-α, which supports restoration of control and regulation of the immune system.
“Our
Company’s new name and stock identity comes at an important time in our clinical development of MYMD-1, illuminating both our core
science and our clinical candidate’s strong potential to be the first TNF-α inhibitor in this indication,” said the
Company’s President, Chief Medical Officer and Director, Mitchell Glass, M.D.
Effective
today, all stock trading, Securities and Exchange Commission filings and market-related information will be reported under the new trading
symbol “TNFA.” The CUSIP for the Company’s common stock is unchanged. There is no action required by the Company’s
current stockholders with respect to the trading symbol change.
About
TNF Pharmaceuticals, Inc.
TNF
Pharmaceuticals, Inc. (Nasdaq: TNFA), formerly known as MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company
committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather
than only addressing the symptoms. MYMD-1® is a drug platform based on a clinical stage small molecule that regulates the immune
system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being
developed to treat diseases and disorders marked by acute or chronic inflammation. The Company’s second drug platform, Supera-CBD,
is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and
is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products
not currently regulated as drugs. For more information, visit www.tnfpharma.com.
Cautionary
Statement Regarding Forward-Looking Statements
This
press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties
and other factors which may cause actual results, performance or achievements to be materially different from any expected future results,
performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates
assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,”
“estimate,” “expect,” “may,” “plan,” “will,” “would’’ and
other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results
to differ materially from those indicated by such forward-looking statements include, without limitation: the Company’s ability
to maintain compliance with the Nasdaq Stock Market’s listing standards; the timing of, and the Company’s ability to, obtain
and maintain regulatory approvals for clinical trials of the Company’s pharmaceutical candidates; the timing and results of the
Company’s planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical
candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in
which the Company operates; the Company’s ability to retain and attract senior management and other key employees; the Company’s
ability to quickly and effectively respond to new technological developments; and the Company’s ability to protect its trade secrets
or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the
Company’s proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2023, filed by the Company on April 1, 2024, and subsequent reports that the
Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the
Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future
events or otherwise.
Investor
Contact:
Robert
Schatz
(646) 421-9523
rschatz@tnfpharma.com
www.tnfpharma.com
v3.24.2
Cover
|
Jul. 22, 2024 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
Jul. 22, 2024
|
| Current Fiscal Year End Date |
--12-31
|
| Entity File Number |
001-36268
|
| Entity Registrant Name |
TNF
Pharmaceuticals, Inc.
|
| Entity Central Index Key |
0001321834
|
| Entity Tax Identification Number |
22-2983783
|
| Entity Incorporation, State or Country Code |
DE
|
| Entity Address, Address Line One |
855 N. Wolfe Street
|
| Entity Address, Address Line Two |
Suite 623
|
| Entity Address, City or Town |
Baltimore
|
| Entity Address, State or Province |
MD
|
| Entity Address, Postal Zip Code |
21205
|
| City Area Code |
(856)
|
| Local Phone Number |
848-8698
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common stock, par value
$0.001 per share
|
| Trading Symbol |
TNFA
|
| Security Exchange Name |
NASDAQ
|
| Entity Emerging Growth Company |
false
|
| Entity Information, Former Legal or Registered Name |
MyMD
Pharmaceuticals, Inc.
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
| Name: |
dei_CurrentFiscalYearEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:gMonthDayItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
TNF Pharmaceuticals (NASDAQ:TNFA)
Historical Stock Chart
From Oct 2024 to Nov 2024
TNF Pharmaceuticals (NASDAQ:TNFA)
Historical Stock Chart
From Nov 2023 to Nov 2024
